Rilvegostomig

DB18991InvestigationalProtein Based Therapies

Rilvegostomig is under investigation in clinical trial NCT06109779 (Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (Artemide-biliary01)).

Mechanism: Pharmacologically active on Programmed cell death protein 1 and T-cell immunoreceptor with Ig and ITIM domains
Curator reviewed
Code names: AZD-2936

Resolves to

Compound

UNIIYSL2GUT2Q8CAS2640305-01-5

Targets

Q15116PDCD1Q495A1TIGIT

What you can answer from here — as of July 09, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

37Clinical trialsPhase, status and sponsor resolved per trial

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with Rilvegostomig, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account